Cargando…
Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma
BACKGROUND: The chemokine receptor CCR7 mediates lymphoid dissemination of many cancers, including lymphomas and epithelial carcinomas, thus representing an attractive therapeutic target. Previous results have highlighted the potential of the anti-CCR7 monoclonal antibodies to inhibit migration in t...
Autores principales: | Somovilla-Crespo, Beatriz, Alfonso-Pérez, Manuel, Cuesta-Mateos, Carlos, Carballo-de Dios, Cristina, Beltrán, Amada E, Terrón, Fernando, Pérez-Villar, Juan J, Gamallo-Amat, Carlos, Pérez-Chacón, Gema, Fernández-Ruiz, Elena, Zapata, Juan M, Muñoz-Calleja, Cecilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879031/ https://www.ncbi.nlm.nih.gov/pubmed/24305507 http://dx.doi.org/10.1186/1756-8722-6-89 |
Ejemplares similares
-
Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2021) -
Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2021) -
Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9(+) tumors
por: Santamaria, Silvia, et al.
Publicado: (2022) -
CCR7 in Blood Cancers – Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2021) -
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2018)